Image-guided drug delivery: Preclinical applications and clinical translation

Expert Opinion on Drug Delivery

Volumn 12, Issue 8, 2015, Pages 1203-1207

  Ojha, Tarun ^a   Rizzo, Larissa ^a   Storm, Gert ^a,c   Kiessling, Fabian ^a   Lammers, Twan ^a,b,c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Drug delivery; Imaging; Nanomedicine; Theranostics

Indexed keywords

BLEOMYCIN; DOXORUBICIN; NANOCARRIER; POLYMER; VINCRISTINE;

BREAST CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG TARGETING; FLUORESCENCE; HUMAN; IMAGING; KAPOSI SARCOMA; NANOMEDICINE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; ANIMAL; DIAGNOSTIC IMAGING; PROCEDURES; TISSUE DISTRIBUTION;

ANIMALS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; HUMANS; NANOMEDICINE; TISSUE DISTRIBUTION;

EID: 84937206639     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2015.1059420     Document Type: Review

References (14)

1. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009;3:16-20
2. Moghimi SM, Peer D, Langer R. Reshaping the future of nanopharmaceuticals: Ad Iudicium. ACS Nano 2011;5:8454-8
3. Rizzo LY, Theek B, Storm G, et al. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol 2013;24:1159-66
4. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011;63:136-51
5. Lammers T, Kiessling F, Hennink W, et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012;161:175-87
6. Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Caner Res 2013;73:2412-17
7. Kunjachan S, Gremse F, Theek B, et al. Non-invasive optical imaging of nanomedicine biodistribution. ACS Nano 2013;7:252-62
8. Kunjachan S, Pola R, Gremse F, et al. Passive vs. active tumor targeting using RGD-and NGR-modified polymeric nanomedicines. Nano Lett 2014;14:972-98
9. Gruell H, Langereis S. Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound. J Control Release 2012;161:317-27
10. Negussie AH, Yarmolenko PS, Partanen A, et al. Formulation and characterisation of magnetic resonanceguided high intensity focused ultrasound. Int J Hyperthermia 2011;27:140-55
11. Koukourakis MI, Koukourakis S, Giatromanolaki A, et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas. Acta Oncol (Madr) 2000;39:207-11
12. Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabled pegylated-liposomes. Clin Cancer Res 2001;7:243-54
13. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445-51
14. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/ Doxil) vs. conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-